Nasdaq:US$15.42 (-0.39) | HKEX:HK$25.30 (+0.80) | AIM:£2.36 (+0.1)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors